Clinical Trials Logo

Breast Cancer clinical trials

View clinical trials related to Breast Cancer.

Filter by:

NCT ID: NCT05625087 Recruiting - Clinical trials for Breast Cancer Stage IV

Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib

SAFIR 03
Start date: October 19, 2023
Phase: Phase 2
Study type: Interventional

After an initial screening phase (SAFIR 03 - SCREENING) to identify patients with blood circulating mutated-PIK3CA tumours persistent, patients will be enrolled in the treatment phase of SAFIR 03 (SAFIR 03 - ARRIBA) that was designed as a randomised, open-label, multicentre, phase II study, for comparison of alpelisib to ribociclib in combination with fulvestrant (as the continuation of the CDK4/6 inhibitor-fulvestrant strategy) in terms of progression-free survival (PFS).

NCT ID: NCT05623488 Recruiting - Breast Cancer Clinical Trials

CAR T Cells in Mesothelin-Expressing Breast Cancer

Start date: February 6, 2023
Phase: Phase 1
Study type: Interventional

Phase 1 - Safety and Proof of Concept

NCT ID: NCT05623397 Recruiting - Breast Cancer Clinical Trials

A Deep Learning Method to Evaluate QT on Ribociclib

QT-RIBRATING
Start date: July 28, 2023
Phase:
Study type: Observational

"Deep-learning" is a fast-growing method of machine learning (artificial intelligence, AI) which is arousing the interest of the scientific committee in many medical fields. These methods make it possible to generate matches between raw inputs (such as the digital signal from the ECG) and the desired outputs (for example, the measurement of QTc). Unlike traditional machine learning methods, which require manual extraction of structured and predefined data from raw input, deep-learning methods learn these functionalities directly from raw data, without pre-defined guidelines. With the advent of big-data and the recent exponential increase in computing power, these methods can produce models with exceptional performance. The investigators recently used this type of method using multi-layered artificial neural networks, to create an application based on a model that directly transforms the raw digital data of ECGs (.xml) into a measure of QTc comparable to those respecting the highest standards concerning reproducibility. The main purpose of this trial is to study the performance of our DL-AI model for QTc measurement (vs. best standards of QTc measurements, TCM) applied to the recommended ECG monitoring following ribociclib prescription for breast cancer patients in routine clinical care. The investigators will acquire ECG with diverse devices including simplified devices (one/three lead acquisition, low frequency sampling rate: 125-500 Htz) to determine if they'll be equally performant versus 12-lead acquisition machine to evaluate QTc in this setting.

NCT ID: NCT05623280 Recruiting - Breast Cancer Clinical Trials

Artificial Intelligence Analysis of Fluorescence Image to Intraoperatively Detect Metastatic Sentinel Lymph Node.

Start date: November 1, 2021
Phase:
Study type: Observational

The purpose of this study is to analysis the fluorescence image of the breast sentinel lymph node (SLN) using Indocyanine green (ICG). Moreover, to investigate whether an artificial intelligence protocol was suitable for identifying metastatic status of SLN during the surgery, and evaluate the diagnosis consistency of the AI technique and pathological examinations for lymph node with and without metastasis.

NCT ID: NCT05623241 Recruiting - Breast Cancer Clinical Trials

MONOCENTRIC PERSPECTIVE STUDY: USE OF LIQUID BIOPSY WITH DIAGNOSTIC IMAGING

Start date: September 12, 2022
Phase:
Study type: Observational

Evaluation of the diagnostic accuracy of Mammography in the morpho-structural analysis of mammographic images in breast cancer-diagnosed patients or patients in follow-up for breast cancer by extracting a number of features describing the texture and morphology of the lesions reported in the form of a structured report explicitly developed for the study. Correlation of the data obtained from evaluating the primary endpoint with the genetic/molecular analysis on liquid biopsy.

NCT ID: NCT05622240 Recruiting - Breast Cancer Clinical Trials

99mTc-MIRC213 SPECT/CT for the Detection of HER2-positive Breast Cancer

Start date: September 7, 2022
Phase: Early Phase 1
Study type: Interventional

This is an open-label single photon emission tomography/computed tomography (SPECT/CT) study to investigate the imaging performance of 99mTc-MIRC213 in breast cancer patients. A single dose of 11.1-14.8Mega-Becquerel (MBq) per kilogram body weight 99mTc-MIRC213 will be injected intravenously. Visual and semiquantitative method will be used to assess the SPECT/CT images.

NCT ID: NCT05622227 Recruiting - Breast Cancer Clinical Trials

68Ga PET/CT Imaging in Breast Cancer Patients

Start date: November 15, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

PSMA is highly expressed on the cell surface of the microvasculature of several solid tumors, including breast cancer. This makes it a potentially imaging target for the detection and grading of breast cancer. This pilot study was designed to evaluate the diagnostic performance of 68Ga-P16-093, a novel radiopharmaceutical targeting PSMA, which was compared with 18F-FDG in the same group of breast cancer patients.

NCT ID: NCT05621837 Recruiting - Breast Cancer Clinical Trials

Quantifying Systemic Immunosuppression to Personalize Cancer Therapy

Serpentine
Start date: March 10, 2022
Phase:
Study type: Observational

The Serpentine (Stratify cancER PatiENTs by ImmuNosupprEssion) project, represents the most consistent effort so far attempted to translate MDSC into clinical practise by producing an off-the-shelf compliant assay for quantifying these cells in peripheral blood.

NCT ID: NCT05621564 Recruiting - Breast Cancer Clinical Trials

Pre-operative Therapy in Breast Cancer

Start date: November 1, 2022
Phase:
Study type: Observational

This is a prospective and retrospective study to evaluate the effect of pre-operative therapy on response and survival, and compare the difference in response and survival by pre-operative regimen or by patient's clinicopathological characteristic in early or advanced breast cancer.

NCT ID: NCT05620329 Recruiting - Breast Cancer Clinical Trials

UNC Pleural Fluid Registry

Start date: January 24, 2018
Phase:
Study type: Observational [Patient Registry]

Research with biospecimens such as blood, tissue, or body fluids can help researchers understand how the human body works. Researchers can make new tests to find diseases, understand how treatments work, or find new ways to treat a disease. The purpose of this study is to collect biospecimens for research from patients with known or suspected lung cancer. The information learned from the biospecimens may be used in future treatments. The purpose of this protocol is to create a pleural fluid registry for use in future studies.